Petmed Express Inc (NASDAQ:PETS) Director Robert C. Schweitzer sold 7,500 shares of the firm’s stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $37.00, for a total transaction of $277,500.00. Following the transaction, the director now directly owns 88,334 shares of the company’s stock, valued at $3,268,358. The sale was disclosed in a document filed with the SEC, which is available through this link.

NASDAQ PETS opened at $36.80 on Friday. Petmed Express Inc has a one year low of $31.81 and a one year high of $57.80. The stock has a market capitalization of $749.02 million, a PE ratio of 18.20 and a beta of 0.54.

Petmed Express (NASDAQ:PETS) last posted its quarterly earnings results on Monday, July 23rd. The company reported $0.62 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.63 by ($0.01). Petmed Express had a net margin of 14.42% and a return on equity of 35.77%. The business had revenue of $87.39 million during the quarter, compared to analyst estimates of $85.72 million. During the same period last year, the firm posted $0.45 earnings per share. The company’s quarterly revenue was up 9.7% on a year-over-year basis. analysts anticipate that Petmed Express Inc will post 2.28 earnings per share for the current fiscal year.

PETS has been the subject of several recent analyst reports. BidaskClub lowered shares of Petmed Express from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 25th. ValuEngine lowered shares of Petmed Express from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 24th. Zacks Investment Research lowered shares of Petmed Express from a “buy” rating to a “hold” rating in a report on Tuesday, July 10th. Craig Hallum reaffirmed a “sell” rating and issued a $32.00 price target (down from $38.00) on shares of Petmed Express in a report on Monday, July 9th. Finally, CL King started coverage on shares of Petmed Express in a report on Friday, June 15th. They issued a “neutral” rating for the company. Three analysts have rated the stock with a sell rating, three have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. Petmed Express has an average rating of “Hold” and a consensus target price of $36.75.

Hedge funds and other institutional investors have recently bought and sold shares of the company. TD Asset Management Inc. bought a new stake in Petmed Express in the 2nd quarter valued at about $2,652,000. First Trust Advisors LP lifted its position in Petmed Express by 36.7% in the 2nd quarter. First Trust Advisors LP now owns 76,829 shares of the company’s stock valued at $3,384,000 after purchasing an additional 20,634 shares during the last quarter. Alps Advisors Inc. lifted its position in Petmed Express by 19.5% in the 2nd quarter. Alps Advisors Inc. now owns 12,289 shares of the company’s stock valued at $559,000 after purchasing an additional 2,007 shares during the last quarter. Personal Capital Advisors Corp lifted its position in Petmed Express by 17.6% in the 2nd quarter. Personal Capital Advisors Corp now owns 95,369 shares of the company’s stock valued at $4,201,000 after purchasing an additional 14,281 shares during the last quarter. Finally, Comerica Bank lifted its position in Petmed Express by 15.6% in the 2nd quarter. Comerica Bank now owns 24,938 shares of the company’s stock valued at $1,003,000 after purchasing an additional 3,361 shares during the last quarter. 95.68% of the stock is owned by institutional investors and hedge funds.

Petmed Express Company Profile

PetMed Express, Inc engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins and nutritional supplements, and hygiene products.

Recommended Story: Calculate Your Return on Investment (ROI)

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.